Among lung cancer patients treated with ICIs, PD‐L1+ exosome levels prior to treatment were significantly higher in non‐responders compared to responders, demonstrating predictive value surpassing conventional tumor PD‐L1 immunohistochemistry. This evidence concerns the gene CD274 and lung carcinoma.